Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

23.98 -0.22 (-0.91%)
Streaming Delayed Price Updated: 12:01 PM EDT, May 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Looking for the most active stocks in the S&P500 index on Wednesday?
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Wednesday and discover the stocks that are dominating the trading activity and setting the pace... 
Via Chartmill
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway. 
Via Benzinga
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
From Pfizer Inc.
Via Business Wire
Novavax Signals Chances Of FDA Approval For Its COVID-19 Vaccine: But Retail Sentiment Wavers
The company announced on Wednesday that it had received formal communication from the FDA in the form of an information request for a “postmarketing commitment” to generate additional clinical data. 
Via Stocktwits
Topics Government
Exposures COVID-19 Political Product Safety
3 of Wall Street’s Favorite Stocks Walking a Fine Line
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
2 High-Yield Dividend Stocks to Buy for Passive Income
Via The Motley Fool
Topics Retirement
Exposures COVID-19 Pension
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
Via Benzinga
Topics Government
Exposures Political
Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY
Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients. 
Via MarketBeat
What's Next for Pfizer After the Company Pulls Its Weight Loss Drug?
Via The Motley Fool
Is Eli Lilly Stock a Buy?
The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up. 
Via The Motley Fool
S&P 500 Sell-Off: 2 Ultra-High-Yield Dividend Stocks That Make for No-Brainer Buys
Two brand-name, time-tested companies -- sporting an average yield of 7% -- are ripe for the picking amid a historic bout of volatility on Wall Street. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Via The Motley Fool
Forecasting The Future: 6 Analyst Projections For Pfizer
Via Benzinga
Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline
Pfizer Inc (NYSE:PFE) is scheduled to release its first quarter 2025 earnings on 29 April. 
Via Benzinga
Topics Earnings
Exposures Financial
How To Put $100 In Your Retirement Fund Each Month With Pfizer Stock
Via Benzinga
Topics Retirement
Exposures Pension
Hertz Global And Webull Stocks Are Among Top Mid-Cap Gainers Last Week (Apr 14-Apr 18): Are The Others In Your Portfolio?
Top mid-cap performers last week: Webull Corp, Hertz Global, Metsera Inc, Vista Energy, Certara Inc, Sibanye-Stillwater, Banco Macro, Grupo Financiero Galicia, Banco BBVA Argentina, Recursion... 
Via Benzinga
3 Ultra-High-Yield Dividend Stocks to Buy Right Now That Are Dirt Cheap
Via The Motley Fool
Topics Economy Energy
Exposures Climate Economy Fossil Fuels
A Once-in-a-Decade Opportunity: 3 Magnificent Stocks Down Between 40% and 73% to Buy Right Now
Via The Motley Fool
3 Magnificent Stocks to Buy That Are Near 52-Week Lows
Via The Motley Fool
Topics Economy Government
Exposures COVID-19 Economy Political
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock?
Via The Motley Fool
Where Will Eli Lilly Be in 5 Years?
Via The Motley Fool
3 Magnificent S&P 500 Dividend Stocks Down 11% to 63% to Buy and Hold Forever
As tough as it may be to do right now, this is a great time to hold your nose and dive in while yields are as high as they are. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Thursday's session: most active stock in the S&P500 index
Looking for the most active stocks in the S&P500 index on Thursday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market. 
Via Chartmill
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years
CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older populations. 
Via Benzinga
Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential
Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary endpoint of A1C reduction. Analysts see potential for sales of $10 billion by... 
Via Benzinga
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding. 
Via The Motley Fool
Mark Cuban Says This Trump Healthcare Order 'Could Save Hundreds Of Billions'
Billionaire entrepreneur Mark Cuban has expressed support for President Donald Trump's 2025 healthcare executive order, emphasizing its potential to reform the role of Pharmacy Benefit Managers (PBMs)... 
Via Benzinga
Topics Government
Exposures Political
2 of Wall Street’s Favorite Stocks with Competitive Advantages and 1 to Be Wary Of
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Eli Lilly Stock Rockets On Weight-Loss Pill Progress
Eli Lilly's pill-form weight loss drug cansdidate cleared one of several Phase III hurdles. 
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars
Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable safety profile. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.